total revenue vs non-gaap ep vs beat consensu due
larg strength hiv franchis well tax benefit hiv continu
perform declin hcv franchis moder hope gilead
trough earn pass remain outperform
world-wide hiv sale q/q y/i consensu
strength driven launch taf pill notabl biktarvi though
gilead note chang payer mix quarter led
approxim benefit hcv sale q/q y/i also
consensu total revenu q/q
y/i beat estim consensu gilead report non-
gross margin vs non- sg expens
revenu revenu vs
respect gilead report tax rate vs due favor settlement
tax examin non-gaap ep q/q y/i consensu
full year non-gaap effect tax rate gilead lower
guidanc guidanc net product sale gross
margin expens sg expens
reiter increas product sale estim
increas non-gaap ep estim dcf-base price
hiv sale includ viread vemlidi q/q y/i
consensu strength due perform gilead
 busi q/q y/i vs gilead attribut q/
 strength three factor stabil inventori compar chang
payer mix toward commerci payer continu strong launch
biktari normal payer mix gilead hiv franchis consist
commerci govern howev mix shift even
split commerci govern gilead estim provid approxim
demand trend busi remain healthi prescript y/i
biktarvi launch continu strong trajectori far compar
genvoya gilead report sale biktarvi demand larg
driven switch regimen includ switch patient
dolutegravir regimen consult suggest base ph
data biktarvi becom clear first choic regimen biktarvi approv
eu june launch germani sever european countri
gilead report taf-bas regimen account gilead hiv prescript
volum slightli end
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t
oncolog platform kite expect combin launch new
taf-bas combin pill hiv market growth share gain price increas
hiv franchis sale grow compound-annual-growth-rate despit viread patent
expir gilead hcv franchis struggl declin patient volum new
competit erod sale project gilead hcv franchis gener world-wide
sale declin expect partial off-set pipelin program includ
yescarta filgotinib base dcf analysi gilead stock under-valued
result filgotinib finch studi
possibl eu approv yescarta anhl
data ph ii studi fxr agonist
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv fungal infect
acquir car-t oncolog platform kite gilead antivir portfolio biggest
revenu driver gilead lead hiv franchis anchor tenofovir well-toler
efficaci nucleotid analog gilead develop sever tenofovir-bas
combin pill includ truvada atripla complera stribild genvoya odefsey
descovi togeth captur share treatment-na hiv patient
drive hiv franchis revenu project revenu
hcv franchis led sofosbuvir nucleosid inhibitor result phase trial
sofosbuvir-bas regimen shown potent well toler high
barrier viral resist expect hcv franchis maintain revenu
hcv price market share slowli stabil
 hcv revenu q/q y/i ex-u hcv revenu
q/q y/i declin though blend rate q/q well
q/q gilead believ price stabil share loss also
moder percentag point q/q week manag remain
hope stabl predict busi price share
consist slow steadi declin hcv market patient start hcv
estim materi unchang
gilead record revenu yescarta second full quarter market ahead
consensu estim though gilead continu
suggest yescarta ramp measur new center train
cancer center author treat patient gilead estim
yescarta-elig patient patient access center
new center continu author manag indic focu
shift increas patient flow part via educ effort commun oncologist
direct patient author center gilead note patient cover
commerci insur effort continu improv access medicar
approv yescarta eu anticip follow posit chmp opinion
june prepar launch europ underway plan author
least center year end initi focu launch germani franc
anticip european approv yescarta gilead leas manufactur facil
netherland come on-lin yescarta uptak strong thu far
model yescarta revenu
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin initi pivot
phase ii yescarta r/r indol nhl set complet enrol
addit gilead expect complet enrol pivot ph ii
construct yescarta differ manufactur mcl
initi pivot phase ii adult pediatr
gilead also highlight recent progress pipelin develop inflamm
five phase studi filgotinib on-going rheumatoid arthriti ulcer coliti
crohn diseas phase trial ra fulli enrol finch
data finch expect later quarter data readout
expect filgotinib succeed phase ii equat trial
psoriat arthriti pass interim futil analysi phase iib/iii trial uc phase ii
studi filgotinib sever inflammatori diseas also on-going studi
anklyos spondyl set complet
result selorsertib stellar stellar phase nash
anticip gilead expect studi posit may file
regulatori approv success could first bring product
investor desper wait gilead revenu trough two year declin
look sign gilead pois re-rat gilead revenu ep
beat consensu estim hope gilead trough earn
pass turn gilead fundament may near particular
prescript gilead hiv franchis y/i demand trend fundament
busi remain strong fact biktarvi earli launch suggest help gilead
regain share dolutegravir regimen hiv remain bright spot hcv sale still
declin appear stabil manag continu expect slow predict
declin sale go forward driven primarili declin patient start price
market share begin find equilibrium
though yescarta revenu remain round error rest gilead busi
launch impress thu far make us hope meaning
contributor futur all-in-al long-term project remain intact gilead
trade ep project free cash flow yield continu
believ under-valued cash flow
gilead develop market treatment hiv hbv hcv fungal infect
gilead antivir portfolio largest revenu driver next sever year
gilead lead hiv franchis anchor tenofovir well-toler efficaci
nucleotid analog gilead hiv franchis gener
revenu captur share patient newli initi hiv therapi
tenofovir disoproxil fumar viread lost patent protect gilead develop
second gener version tenofovir alafenamid taf improv safeti
extend patent protect project sale gilead hiv franchis grow
launch new patent-protect combin pill
biktarvi bic/f/taf genvoya e/c/f/taf descovi f/taf odefsey e/r/taf
taf regimen extend commerci life franchis gilead hcv franchis
built around sovaldi nucleosid inhibitor whose potenc high barrier
resist made cornerston market-lead all-or hcv combin
sovaldi launch decemb eu januari
approv gilead harvoni sofosbuvir ledispavir octob brought
first fda-approv interferon free regimen genotyp hcv patient largest
hcv popul hcv franchis got fast start post
revenu unfortun best day gilead hcv franchis
past emerg competit gild hcv franchis gener
revenu estim continu declin gilead recent
expand oncolog franchis acquisit kite gilead
gain yescarta car-t therapi anhl approv fda octob
well lead car-t platform cowen project yescarta achiev
revenu third line anhl hope gilead trough
earn final sight two year rapid declin hcv revenu
project non-gaap ep non-gaap ep grow
compound-annual-growth-rate gilead current trade forward pe project
cash flow yield base dcf analysi gilead stock under-valued
result filgotinib finch studi ra
possibl eu approv yescarta aggress nhl
complet enrol phase ii combo zuma
data phase ii studi fxr agonist nash
complet phase ii studi filgotinib ankylos spondyl
phase ii data cutan lupu erythematosu
complet phase ii ebola
year follow-up data zuma
complet enrol phase ii yescarta r/r indol nhl zuma
initi phase iib combo zuma
complet enrol phase ii mcl zuma
initi pivot phase ii adult zuma
initi pivot phase ii ped zuma
initi phase cll zuma
complet enrol phase ia studi anti-bcma mm
decis registr studi anti-bcma base phase data
complet enrol ph ia mage solid tumor
file ind tcr target solid tumor
phase ii data tirabrutinib idelalisib entospletinib r/r cll
data phase data selonsertib nash stellar
data filgotinib finch studi ra
data filgotinib finch studi ra
complet enrol ph select studi filgotinib ulcer coliti
data phase ii sjogern syndrom
complet phase trial descovi prep
data phase studi selonsertib nash stellar
complet phase studi hiv cure
interim data combin studi nash
complet enrol filgotinib divers studi crohn diseas
complet enrol phase line dlbcl zuma
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest incom loss attribut non-controlling net gaap fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
